In a 12‑week observational study, 51 volunteers took Elcella capsules and reported an average 6kg weight loss and 94% improvement in appetite control, according to the supplement’s own data. The product, developed by Dr Madusha Peiris and Dr Rubina Aktar of Queen Mary University of London, claims to mimic the appetite‑suppressing hormones released by GLP‑1 drugs by delivering specific fatty acids to the colon’s enteroendocrine cells.

Queen Mary’s science behind the “natural Mounjaro” claim

Peiris and Aktar explain that enteroendocrine L‑cells in the colon release GLP‑1 and PYY when exposed to alpha‑linolenic, lauric, capric and caprylic acids. the researchers created a coated capsule that protects these fatty acids from stomach digestion, allowing them to reach the colon. According to the source, this precise mechanism is what “tames appetite” without the nausea and diarrhoea often seen with GLP‑1 injections.

Trial results that sound too good to be true

The supplement’s own 12‑week observational evaluation involved 51 participants, of whom 34 completed the trial. the reported outcomes were a 94% improvement in appetite control and an average weight loss of 6kg (13 pounds), with a waist reduction of 7cm (2.76 inches). Jane Alexander, a user quoted in the source, noted that she lost up to nine pounds in a single week and felt “over the moon” after two weeks of use.

Regulatory status and safety concerns

Elcella is marketed as a supplement, meaning it is regulated as a food product rather than a drug and does not require MHRA approval. The source reports that users did not experience the nausea, vomiting or diarrhoea commonly associated with GLP‑1 injections. However, the supplement’s safety profile remains unverified by independent trials,and the long‑term effects of chronic fatty‑acid delivery to the colon are unknown.

Who is the unnamed buyer?

The source does not disclose who is funding the 12‑week study or whether the researchers have any commercial ties to the Elcella company. This lack of transparency raises questions about potential conflicts of interest and the independence of the reported data.

Is the appetite suppression real or placebo?

While the trial data are promising, the source acknowledges that the observed weight loss could be influenced by placebo effects or dietary changes during the study period. The supplement’s claim that it can replace GLP‑1 injections without side effects remains unverified by large,randomized controlled trials .